Bayer AG
Bayer AG (BAYRY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bayry · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bayer AG (BAYRY) measures how much investors pay for each dollar of the company's trailing earnings. BAYRY's current PE ratio of N/A is calculated by dividing its stock price of $10.26 by its TTM earnings per share of -$2.19.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 16 fiscal years · Front-end computedMinQ1 · 25%23.9x
MedianQ3 · 75%45.8x
Max
At N/A, BAYRY's current P/E is lower than in 0% of its annual fiscal year readings over the past 16 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bayer AGYou BAYRY | $40.3B | N/A | — | -$2.19 |
 Astellas Pharma Inc. ALPMF | $23.7B | 15.65x | -32.5% | $163.79 |
 Astellas Pharma Inc. ALPMY | $24.2B | 14.92x | -35.7% | $172.58 |
 Fresenius SE & Co. KGaA FSNUF | $32.1B | 21.21x | -8.6% | $2.24 |
 Grifols, S.A. GIKLY | $14.2B | 18.68x | -19.5% | $0.28 |
 JD Health International Inc. JDHIF | $18.7B | 32.02x | +38.0% | $1.66 |
 Orion Oyj ORINY | $21.4B | 36.71x | +58.3% | $0.85 |
Industry Average 6 peers with valid PE | — | 23.20x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.88 | — | |
2024-12-31 FY2024 | — | $-0.65 | — | |
2023-12-31 FY2023 | — | $-0.75 | — | |
2022-12-31 FY2022 | 11.37x | $1.06 | -75.2% | |
2021-12-31 FY2021 | 45.82x | $0.25 | — | |
2020-12-31 FY2020 | — | $-3.96 | — | |
2019-12-31 FY2019 | 29.22x | $0.62 | -14.1% | |
2018-12-31 FY2018 | 34.01x | $0.45 | +175.7% | |
2017-12-31 FY2017 | 12.34x | $2.10 | -32.2% | |
2016-12-31 FY2016 | 18.19x | $1.36 | -21.3% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bayer AG (BAYRY) measures how much investors pay for each dollar of the company's trailing earnings. BAYRY's current PE ratio of N/A is calculated by dividing its stock price of $10.26 by its TTM earnings per share of -$2.19.
Frequently asked questions
BAYRY pe ratio · 6 questionsBAYRY's current PE ratio is N/A as of 2026-06-08, based on a stock price of $10.26 and TTM EPS of -$2.19. Data sourced from Financial Modeling Prep via BAYRY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bayer AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08